VolitionRX ends Q3 with $16.4 million cash, moves from R&D to commercial cancer screening companyProactive Investors • 11/15/22
VolitionRx Limited Announces Third Quarter 2022 Financial Results and Business UpdatePRNewsWire • 11/14/22
VolitionRx teams up with leading French veterinary group to assess potential of cancer screening technologyProactive Investors • 11/14/22
VolitionRX launches Nu.Q cancer-screen test for dogs in US, preps for European launch by HeskaProactive Investors • 11/03/22
Volition Announces the Launch of the Nu.Q® Vet Cancer Screening Test in the U.S. and Europe Through Heska's Reference LaboratoriesPRNewsWire • 11/03/22
VolitionRX inks global agreement to provide Nu.Q cancer detection test to veterinariansProactive Investors • 10/20/22
Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS TherapeuticsAccesswire • 10/11/22
VolitionRx adds marketing executive Mickie Henshall to its board of directorsProactive Investors • 08/16/22
VolitionRx Limited (VNRX) CEO Cameron Reynolds on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/13/22
VolitionRx ends 2Q with $16.7M, secures further funding to advance trials and commercialization effortsProactive Investors • 08/10/22
VolitionRx Limited Announces Second Quarter 2022 Financial Results and Business UpdatePRNewsWire • 08/10/22
VolitionRx to participate in US clinical study for NETs in sepsis cancer patientsProactive Investors • 08/10/22
VolitionRx appoints DXOCRO to undertake development and clinical validation studies for its Nu.Q product portfolio in the USProactive Investors • 08/08/22
VolitionRx Limited to Present at Investor Summit Group's Q3 Virtual ConferenceNewsfile Corp • 08/03/22
VolitionRx Limited Announces Closing of $6.9 Million Underwritten Public Offering of Common StockPRNewsWire • 08/02/22
VolitionRx Limited inks R&D collaboration deals with Xenetic Biosciences and Salarius Pharmaceuticals in push to develop cancer treatmentsProactive Investors • 08/02/22
Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of CancerAccesswire • 08/02/22